Casana, a Rochester, N.Y.-based healthcare technology company, raised $30M in Series B funding.
The round, which brought the total capital raised to date to $46m, was led by Morningside with participation from Matrix Partners, as well as Series A investors General Catalyst and Outsiders Fund.
The company intends to use the funds to to accelerate FDA submission of the Heart Seat with the goal to obtain FDA approval and bring this important new device to patients in 2022.
Founded in 2018 by Dr. Nicholas Conn, and led by CEO Austin McChord, Casana provides healthcare technologies that enable integrated, in-home health monitoring. Casana’s first product, The Heart Seat™ is an IoT health monitoring toilet seat that captures clinically relevant measurements, including heart rate, blood pressure, and blood oxygenation.
The company is currently pursuing FDA clearance for The Heart Seat. Casana is also investing in several studies to investigate the potential value of The Heart Seat for health systems and risk-bearing organizations.
FinSMEs
23/01/2022